Christoffer Merrild

c-merrild.bsky.social

18 September 2026 06:23

Enormously grateful to my PI, @clemmensenc.bsky.social, Jonas Odgaard Petersen, and the whole team across the Clemmensen, @adeshmukh.bsky.social and @tunepers.bsky.social at @cbmr.science and Fritzen Group at BMI - this was a true collaborative effort and I couldn't be more thankful.

Christoffer Merrild

c-merrild.bsky.social

18 September 2026 06:23

Result: synergistic, dose-dependent weight loss beyond either drug alone, better metabolic markers, and some experimental doses supports suppression in food intake without causing aversion.

Christoffer Merrild

c-merrild.bsky.social

18 September 2026 06:21

It's out now in Nature Metabolism 💉 Most obesity meds hit 1-2 hormone receptors (GLP-1R ± GIPR), and they're quite effective, but doses a being pushed to achieve greater weight loss = more side effects. We combined retatrutide (GLP-1R/GIPR/GCGR) with cagrilintide (AMLNR/CALCR) in obese rats.

Christoffer Merrild

c-merrild.bsky.social

22 April 2026 13:50

I am proud to have done this work alongside @johansenvbi.bsky.social under the supervision of Pablo Ranea-Robles and @clemmensenc.bsky.social at @cbmr.science, University of Copenhagen. Curious to learn more? Read it here: doi.org/10.1113/JP28...